Table 2.

All-cause, CVD, and non-CVD mortality, as well as cardiovascular outcomes and mortality by baseline eGFR for the chlorthalidone, amlodipine, and lisinopril antihypertensive treatment groups

eGFRTotal Number of Events/Participants10-Yr Rate/100 ParticipantsHR (95% CI)PHR (95% CI)P
CALCALA Compared with CL Compared with C
All-cause mortality5019/143702933/84922897/848833.432.932.60.98 (0.94–1.03) 0.400.97 (0.93–1.02) 0.23
 ≥901033/3606619/2245616/217627.826.427.10.96 (0.87–1.06) 0.390.99 (0.90–1.10)0.88
 60–892659/81991536/47681529/481130.630.430.30.98 (0.92–1.04) 0.520.97 (0.91–1.04) 0.40
 <601327/2565778/1479752/150149.950.847.71.03 (0.94–1.13) 0.510.96 (0.88–1.05) 0.36
CVD mortality21981300126316.316.015.70.99 (0.93–1.06) 0.840.97 (0.90–1.04) 0.36
 ≥9038725224111.611.611.21.04 (0.89–1.22)0.631.04 (0.88–1.22) 0.66
 60-89119168466915.314.814.60.97 (0.89–1.07) 0.580.95 (0.87–1.05) 0.30
 <6062036435327.027.526.61.03 (0.91–1.17) 0.640.96 (0.84–1.10) 0.56
Non-CVD mortality26371511152019.218.818.80.96 (0.90–1.02)0.220.97 (0.91–1.03) 0.36
 ≥9059834034817.115.616.70.91 (0.79–1.04) 0.150.97 (0.85–1.11) 0.64
 60-89137679579617.117.317.20.98 (0.90–1.07) 0.640.98 (0.90–1.07) 0.63
 <6066337637629.829.927.51.00 (0.88–1.13) 0.960.96 (0.85–1.09) 0.53
CHD, total1507/9464884/5572865/554818.818.618.20.98 (0.91–1.07) 0.700.98 (0.90–1.07) 0.66
 ≥90278/2048161/1253147/122215.914.714.10.94 (0.78–1.15) 0.560.89 (0.73–1.09) 0.25
 60–89819/5436511/3173485/318017.518.617.41.05 (0.94–1.18) 0.361.02 (0.91–1.14) 0.73
 <60410/1980212/1146233/114626.323.125.40.88 (0.75–1.04) 0.140.97 (0.82–1.14) 0.70
CVD, total32031922183238.537.937.21.02 (0.96–1.07) 0.590.98 (0.93–1.04) 0.53
 ≥9059738134133.033.331.41.05 (0.92–1.19) 0.460.97 (0.85–1.11) 0.64
 60–891756103899536.335.835.01.01 (0.93–1.09) 0.890.98 (0.90–1.05) 0.53
 <6085050349650.749.549.81.02 (0.92–1.14) 0.691.01 (0.90–1.13) 0.89
Stroke, total99258261212.912.913.80.98 (0.89–1.09) 0.741.06 (0.96–1.17) 0.27
 ≥9018811312011.210.511.60.97 (0.77–1.23) 0.831.09 (0.86–1.37) 0.48
 60–8955831534012.412.213.30.95 (0.83–1.09) 0.451.05 (0.92–1.20) 0.49
 <6024615415216.618.017.91.08 (0.88–1.32) 0.461.06 (0.87–1.30) 0.55
HF, total114374965115.315.914.71.12 (1.02–1.22) 0.020.98 (0.89–1.08) 0.64
 ≥9021014311412.913.011.61.12 (0.91–1.39)0.290.92 (0.73–1.15) 0.47
 60–8961740234213.914.813.31.12 (0.99–1.27) 0.080.96 (0.84–1.09) 0.51
 <6031620419522.723.022.41.12 (0.94–1.33) 0.221.07 (0.89–1.27) 0.49
  • The mortality cohort included 31,350 participants whereas the morbidity and mortality cohort included 20,584 participants. HF indicates those participants with heart failure who were hospitalized or had a fatal event; CVD indicates CVD mortality or first hospitalized nonfatal CVD event such as MI, stroke, or HF; and ESRD indicates start of dialysis or renal transplant. CVD mortality includes death due to CHD, stroke, HF, or other CVD. There were 10,849 deaths: 4761 due to CVD, 5668 due to non-CVD causes, and 420 unknown causes. CVD, cardiovascular disease; eGFR, estimated GFR; C, chlorthalidone; A, amlodipine; L, lisinopril; HR, hazard ratio; 95% CI, 95% confidence interval; CHD, coronary heart disease; HF, heart failure.